Aprocitentan mitigates doxorubicin-induced cardiotoxicity by inhibiting cuproptosis, oxidative stress, and mitochondrial impairments via the activation of sirtuin 7
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.114141 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yu-Fei Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University. Beijing 100020 China; Department of C…. Hauptthemen laut MEDLINE: Cardiotoxicity, Doxorubicin, Sirtuins, Endothelin A Receptor Antagonists. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Doxorubicin (DOX) is a widely used chemotherapy drug for cancer while leads to several cardiac disorders including cardiomyopathy and heart failure. Aprocitentan is a novel dual endothelin-1 receptor antagonist and functions as an effective antihypertensive drug for resistant hypertension. However, the exact roles of aprocitentan in DOX-induced cardiotoxicity remains largely unclear.In this work, we explored potential participants of aprocitentan in DOX-induced cardiotoxicity. Mice were treated with DOX to induce cardiotoxicity, and then received either aprocitentan or tetrathiomolybdate interventions respectively. Compared with controls, DOX-treated mice exhibited cardiac impairments and dysfunction. Notably, aprocitentan or tetrathiomolybdate intervention remarkably mitigated DOX-mediated cardiac cardiotoxicity, as evidenced by alleviated myocardial fibrosis and improved cardiac function. Furthermore, aprocitentan or tetrathiomolybdate administration significantly mitigated myocardial cuproptosis, oxidative stress, cardiac aging and inflammation in DOX-treated mice with decreased levels of DLAT accumulation, as well as downregulated expressions of HSP70, P16 and P21, respectively. In cultured primary rat cardiomyocytes, treatment with aprocitentan alleviated DOX-induced augmentation of cuproptosis and oxidative stress with reduced DLAT accumulation. Moreover, aprocitentan administration strikingly reversed DOX-induced and elesclomol-aggravated cellular senescence and mitochondrial injury in cardiomyocytes. More importantly, knock-down of sirtuin 7 (SIRT7) by SIRT7 siRNA blocked the beneficial effects of aprocitentan on DOX-associated cuproptosis, oxidative stress, mitochondrial injury, and senescence in cardiomyocytes. In summary, aprocitentan exerts as a novel therapeutic agent for alleviation of DOX-induced cardiotoxicity through the inhibition of cuproptosis, oxidative stress, cardiac aging and mitochondrial injuries via the activation of SIRT7, offering new possibilities for prevention and treatment of DOX-induced cardiac disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University. Beijing 100020 China; Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beij…
- Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020 China.
- Medical Research Center, Beijing Chaoyang Hospital and Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing 100020 China.
- Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University. Beijing 100020 China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Chen, Y. F., Qi, R. Q., Zhao, L., Liang, L. R., Song, J. W., Zhou, X. Y., Chen, Y. H., Wang, S. Y., Wang, Q., Liu, Y., Dong, Y., Liu, X. Y., Li, J., & Zhong, J. C. (2025). Aprocitentan mitigates doxorubicin-induced cardiotoxicity by inhibiting cuproptosis, oxidative stress, and mitochondrial impairments via the activation of sirtuin 7. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114141
Vancouver
Chen YF, Qi RQ, Zhao L, Liang LR, Song JW, Zhou XY, et al. Aprocitentan mitigates doxorubicin-induced cardiotoxicity by inhibiting cuproptosis, oxidative stress, and mitochondrial impairments via the activation of sirtuin 7. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114141
BibTeX
@article{Chen2025,
author = {Chen, Yu-Fei and Qi, Rui-Qiang and Zhao, Lin and Liang, Li-Rong and Song, Jia-Wei and Zhou, Xin-Yu and Chen, Yi-Hang and Wang, Si-Yuan and Wang, Qi and Liu, Ying and Dong, Ying and Liu, Xiao-Yan and Li, Jing and Zhong, Jiu-Chang},
title = {Aprocitentan mitigates doxorubicin-induced cardiotoxicity by inhibiting cuproptosis, oxidative stress, and mitochondrial impairments via the activation of sirtuin 7},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.114141}
}
EUVIMED